CoQ10 (Ubiquinone vs Ubiquinol) UK: Statin Users' Guide

Coenzyme Q10 (CoQ10), also known as ubiquinone in its oxidised form and ubiquinol in its reduced form, is a fat-soluble compound the body produces in nearly every cell. It plays a central role in the mitochondrial electron transport chain — the pathway that generates ATP — and acts as a lipid-soluble antioxidant. The body's CoQ10 synthesis shares the early steps of the mevalonate pathway with cholesterol synthesis. Statin medications, which inhibit HMG-CoA reductase to lower cholesterol, also lower endogenous CoQ10 production by the same mechanism. This is the rationale that has put CoQ10 onto the radar of statin users for the past two decades. Roughly 7–8 million UK adults take a statin (NHS prescribing data, primarily simvastatin, atorvastatin, and rosuvastatin). A non-trivial subset experience statin-associated muscle symptoms (SAMS) — typically myalgia, weakness, or cramping — that can lead to dose reduction or discontinuation. Whether CoQ10 supplementation reduces these symptoms is one of the most-studied questions in the supplement-and-prescription-medication overlap. **Disclaimer.** Nutripedia summarises published research. We do not provide medical advice. Consult a UK GP, NHS pharmacist, or registered dietitian before starting any supplement, especially if pregnant, breastfeeding, on medication, or managing a chronic condition. CoQ10 has clinically meaningful interactions with warfarin and other prescription medications. Statin therapy decisions — including whether muscle symptoms warrant a dose change — are properly made with a prescribing clinician. This article walks through the statin-myopathy evidence (Banach 2015 Mayo Clinic Proceedings meta-analysis), the heart-failure context (Q-SYMBIO, Mortensen 2014), the ubiquinone vs ubiquinol bioavailability debate, the NHS position, and the warfarin interaction.